2-溴-4-乙基噻唑 | 89322-56-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-溴-4-乙基噻唑
• 英文名称: 2-bromo-4-ethyl-1,3-thiazole
• 英文别名: 5-Aethyl-2-brom-thiazol；4-Aethyl-2-brom-thiazol；2-bromo-4-ethyl-thiazole；2-Bromo-4-ethylthiazole
• CAS: 89322-56-5
• 化学式: C₅H₆BrNS
• mdl: MFCD12033479
• 分子量: 192.079
• InChiKey: YQWKKYUKBQHMJG-UHFFFAOYSA-N

物化性质

• 沸点：
  211.0±9.0 °C(Predicted)
• 密度：
  1.585±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2934100090

反应信息

• 作为反应物：
  描述：

  2-溴-4-乙基噻唑 在 四(三苯基膦)钯 、 二甲基亚砜 、 三乙胺 、 palladium dichloride 作用下， 以 乙腈 为溶剂， 反应 7.5h， 生成 1-(1,3-benzodioxol-5-yl)-2-(4-ethyl-1,3-thiazol-2-yl)ethane-1,2-dione
  参考文献：
  名称：

  Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase

  摘要：

  A novel series of 4-thiazolylimidazoles was synthesized as transforming growth factor-beta (TGF-beta) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitors. These compounds were evaluated for their ALK5 inhibitory activity in an enzyme assay and their TGF-beta-induced Smad2/3 phosphorylation inhibitory activity in a cell-based assay. N-{[5-(1,3-benzothiazol-6-yl)-4-(4-methyl-1, 3-thiazol-2-yl)-1H-imidazol-2-yl]methyl}butanamide 20, a potent and selective ALK5 inhibitor, exhibited good enzyme inhibitory activity (IC50 = 8.2 nM) as well as inhibitory activity against TGF-beta-induced Smad2/3 phosphorylation at a cellular level (IC50 = 32 nM). (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.066
• 作为产物：
  描述：

  4-乙基噻唑-2-胺 在 亚硝酸特丁酯 、 copper(ll) bromide 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以40%的产率得到2-溴-4-乙基噻唑
  参考文献：
  名称：

  Optimization of Novel 1-Methyl-1H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber’s Pole Worm

  摘要：

  A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 mu M. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 mu M. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 mu M.

  DOI：

  10.1021/acs.jmedchem.8b01544

文献信息

• Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
  申请人：Li Chun Sing

  公开号：US20090099200A1

  公开（公告）日：2009-04-16

  Azacyclohexane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式I的脂环己基衍生物是选择性抑制硬脂酰辅酶A delta-9去饱和酶（SCD1）相对于其他已知的硬脂酰辅酶A去饱和酶的化合物。本发明的化合物可用于预防和治疗与异常脂质合成和代谢有关的疾病，包括心血管疾病、动脉粥样硬化、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗和肝脂肪变性。
• WO2020112937A5
  申请人：——

  公开号：WO2020112937A5

  公开（公告）日：2022-12-05
• Thiazole, Oxadiazole, and Carboxamide Derivatives of Artemisinin are Highly Selective and Potent Inhibitors of <i>Toxoplasma gondii</i>
  作者：Christopher P. Hencken、Lorraine Jones-Brando、Claudia Bordón、Remo Stohler、Bryan T. Mott、Robert Yolken、Gary H. Posner、Lauren E. Woodard

  DOI：10.1021/jm901857d

  日期：2010.5.13

  We have prepared 23 new dehydroartemisinin (DART) trioxane derivatives (11 thiazoles, 2 oxadiazoles, and 10 carboxamides) and have screened them for in vitro activity in the Toxoplasma lytic cycle. Fifteen (65%) of the derivatives were noncytotoxic to host cells (TD50 >= 320 mu M). Eight thiazole derivatives and two carboxamide derivatives displayed effective inhibition of Toxoplasma growth (IC50 = 0.25-0.42 mu M), comparable in potency to artemether (IC50 = 0.31 mu M) and > 100 times more inhibitory than the currently employed front-line drug trimethoprim (IC50 = 46 mu M). The thiazoles as a group were more effective than the other derivatives at inhibiting growth of extracellular as well as intracellular parasites. Unexpectedly, two thiazole trioxanes (5 and 6) were parasiticidal; both inhibited parasite replication irreversibly after parasite exposure to 10 mu M of drug for 24 h, whereas the standard trioxane drugs artemisinin and artemether were not parasiticidal. Some of the new derivatives of artemisinin described here represent effective anti-Toxoplasma trioxanes as well as molecular probes for elucidating the mechanism of action of the DART class of artemisinin derivatives.
• Optimization of Novel 1-Methyl-1<i>H</i>-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber’s Pole Worm
  作者：Thuy G. Le、Abhijit Kundu、Atanu Ghoshal、Nghi H. Nguyen、Sarah Preston、Yaqing Jiao、Banfeng Ruan、Lian Xue、Fei Huang、Jennifer Keiser、Andreas Hofmann、Bill C. H. Chang、Jose Garcia-Bustos、Abdul Jabbar、Timothy N. C. Wells、Michael J. Palmer、Robin B. Gasser、Jonathan B. Baell

  DOI：10.1021/acs.jmedchem.8b01544

  日期：2018.12.13

  A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 mu M. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 mu M. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 mu M.
• Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase
  作者：Hideaki Amada、Yoshinori Sekiguchi、Naoya Ono、Yuko Matsunaga、Takeshi Koami、Hajime Asanuma、Fumiyasu Shiozawa、Mayumi Endo、Akiko Ikeda、Mari Aoki、Natsuko Fujimoto、Reiko Wada、Masakazu Sato

  DOI：10.1016/j.bmcl.2012.01.066

  日期：2012.3

  A novel series of 4-thiazolylimidazoles was synthesized as transforming growth factor-beta (TGF-beta) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitors. These compounds were evaluated for their ALK5 inhibitory activity in an enzyme assay and their TGF-beta-induced Smad2/3 phosphorylation inhibitory activity in a cell-based assay. N-[5-(1,3-benzothiazol-6-yl)-4-(4-methyl-1, 3-thiazol-2-yl)-1H-imidazol-2-yl]methyl}butanamide 20, a potent and selective ALK5 inhibitor, exhibited good enzyme inhibitory activity (IC50 = 8.2 nM) as well as inhibitory activity against TGF-beta-induced Smad2/3 phosphorylation at a cellular level (IC50 = 32 nM). (C) 2012 Elsevier Ltd. All rights reserved.